Celldex CFO granted 93,000 stock options

Celldex Therapeutics, Inc. reported that its SVP and CFO, Martin Samuel Bates, received an incentive stock option grant covering 93,000 shares of common stock.

Rhea-AI Filing Summary

Celldex Therapeutics, Inc. reported that its SVP and CFO, Martin Samuel Bates, received an incentive stock option grant covering 93,000 shares of common stock. The option has an exercise price of $34.09 per share and was awarded under the company’s 2021 Omnibus Equity Incentive Plan.

According to the vesting schedule, 25% of the options vest on June 25, 2027, with the remaining options vesting in equal quarterly installments over the following 12 quarters, and the option expires on June 25, 2036. After this grant, Bates holds 93,000 incentive stock options directly.

Insider Trade Summary

Grant/Award: 93,000 shares

Grant/Award 1 txn

Insider Martin Samuel Bates

Role SVP AND CFO

Type	Security	Shares	Price	Value
Grant/Award	Incentive Stock Option (right to buy)	93,000	$0.00	$0.00

Holdings After Transaction: Incentive Stock Option (right to buy) — 93,000 contracts (Direct)

Footnotes (2)

1. F1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
2. F2. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Key Figures

Incentive stock options granted: 93,000 options Exercise price: $34.09 per share Options held after grant: 93,000 options +3 more

6 metrics

Incentive stock options granted 93,000 options Grant to SVP and CFO on June 25, 2026

Exercise price $34.09 per share Price to exercise the incentive stock options

Options held after grant 93,000 options Total incentive stock options directly held following transaction

Initial vesting date June 25, 2027 25% of options vest on this date

Remaining vesting period 12 quarters Remaining 75% vests in equal quarterly installments

Expiration date June 25, 2036 Option term end date

Key Terms

Incentive Stock Option, 2021 Omnibus Equity Incentive Plan, vesting, exercise price, +1 more

5 terms

Incentive Stock Option financial

"Incentive Stock Option (right to buy)"

An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.

2021 Omnibus Equity Incentive Plan financial

"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."

vesting financial

"25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price: "34.0900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-25T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Celldex Therapeutics (CLDX) report for Martin Samuel Bates?

Celldex reported that SVP and CFO Martin Samuel Bates received an incentive stock option grant for 93,000 shares. The options relate to Celldex common stock and are structured as a compensation award under the company’s 2021 Omnibus Equity Incentive Plan.

How many stock options did the Celldex (CLDX) CFO receive in this Form 4?

Martin Samuel Bates received an incentive stock option covering 93,000 underlying shares of Celldex common stock. This entire amount reflects a new grant, and following the transaction, he directly holds 93,000 incentive stock options as reported in the filing.

What is the exercise price of the Celldex (CLDX) CFO’s new stock options?

The incentive stock option granted to the Celldex SVP and CFO carries an exercise price of $34.09 per share. This price is the amount he must pay per share to convert the options into Celldex common stock when exercising.

When do the newly granted Celldex (CLDX) stock options start vesting?

The options begin vesting on June 25, 2027, when 25% of the grant vests. The remaining 75% then vest in equal quarterly installments over the subsequent 12 quarters, creating a multi-year vesting schedule tied to continued service.

When do the Celldex (CLDX) CFO’s newly granted options expire?

The incentive stock option grant to the Celldex SVP and CFO expires on June 25, 2036. After that expiration date, any unexercised portion of the 93,000 options can no longer be converted into Celldex common shares.

Under which plan were the Celldex (CLDX) CFO’s options granted?

The Form 4 states that the incentive stock option was granted pursuant to Celldex’s 2021 Omnibus Equity Incentive Plan. This plan provides the framework for equity-based awards like stock options to company executives and employees.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:18 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Martin Samuel Bates

(Last) (First) (Middle)

C/O CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD, SUITE 220

(Street)

HAMPTON NEW JERSEY 08827

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP AND CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right to buy)(1)	$34.09	06/25/2026(1)		A		93,000		06/25/2027(2)	06/25/2036	Common Stock	93,000	$0	93,000	D

Explanation of Responses:

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

2. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

	/s/ Anthony S. Marucci, attorney-in-fact for Samuel Bates Martin	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)